27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Innate Pharma SA (NASDAQ:IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ:AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021.
- The trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).
- After a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab reduced the risk of disease progression or death by 56% (hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.
- The 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.
- The confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).
- AstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.
- Also, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.
- Earlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.
- The analyst was "encouraged" and said a "strong signal" would de-risk a large opportunity for monalizumab and change the narrative around Innate.
- Price Action: IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.
- Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!